Pipeline

3B Pharmaceuticals is focused on the development of targeted therapeutic and diagnostic radiopharmaceuticals for oncology indications with a high medical need. Several programs are developed in partnership with international pharmaceutical companies and are currently in hit identification, lead optimization, preclinical or clinical development. All product candidates originate from 3BP’s internal R&D programs, many of which are based on our mRNA display technology platform for peptide hit identification and subsequent medicinal chemistry optimization. The most advanced radiopharmaceutical drug FAP-2286 is currently tested in Phase I/II clinical trials for the treatment of advanced solid tumors sponsored by Clovis Oncology.